Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Genetic: GSTP1 A313G （AA）
- Registration Number
- NCT06140082
- Lead Sponsor
- LI YAN
- Brief Summary
This study intends to design a retrospective and prospective, cohort study to explore the association between genetic polymorphism of GSTP1 A313G rs1695 or others and adverse effects of platinum drugs, aiming to explore the risk factors of myelosuppression caused by platinum drugs, and provide data support for optimizing anti-tumor chemotherapy regimen, improve medication safety and improve the compliance of chemotherapy in patients.
- Detailed Description
Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy regimen were included in the retrospective and prospective bidirectional cohort study to collect the basic information of the subjects, including gender, age, smoking history, primary site, basic liver and kidney function, chemotherapy regimen, etc. The polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy termination sequencing. To study the risk factors related to myelosuppression during chemotherapy, and to preliminarily explore the characteristics of myelosuppression caused by combination chemotherapy with platinum.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 477
- Patients with non-small cell lung cancer with clear imaging or pathological evidence
- Using a chemotherapy regimen containing platinum
- Conducted blood routine and biochemical tests
- Signed informed consent
- Blood routine and other relevant tests were not performed
- Suffering from primary bone marrow system disease
- Other reasons for not meeting the experimental requirements
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Gene wild-type group GSTP1 A313G （AA） According to the characteristics of the patient's own disease, the clinician develops the corresponding medication regimen, and the patient uses one of the target drugs, cisplatin/carboplatin/nedaplatin/loplatin, or other regimen containing the target drug. Peripheral blood of patients was collected for genetic testing, GSTP1 wild type (AA) was classified into this group, and the time and degree of myelosuppression in this group were recorded.
- Primary Outcome Measures
Name Time Method Incidence of myelosuppression (≤150 days) The platinum-based regimen was followed by 4 to 6 cycles of chemotherapy (each cycle is 28 days), 4 visits per treatment cycle, and day0, day1, day2-5, day6-21 after chemotherapy were recorded Myelosuppression was judged according to WHO grading criteria
- Secondary Outcome Measures
Name Time Method